Search

Your search keyword '"Gambella, Manuela"' showing total 30 results

Search Constraints

Start Over You searched for: Author "Gambella, Manuela" Remove constraint Author: "Gambella, Manuela"
30 results on '"Gambella, Manuela"'

Search Results

1. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study

2. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study

3. Supplementary Appendix from Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing

4. Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR

5. MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients

6. Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing

7. Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma

8. Clinical and Biological Early Relapse Predictors in Multiple Myeloma: An Analysis from the MMRF CoMMpass Study

9. Minimal residual disease by flow cytometry and allelic‐specific oligonucleotide real‐time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis

10. Long Term Outcome of Lenalidomide-Dexamethasone (Rd) Vs Melphalan-Lenalidomide-Prednisone (MPR) Vs Cyclophosphamide-Prednisone-Lenalidomide (CPR) As Induction Followed By Lenalidomide-Prednisone (RP) Vs Lenalidomide (R) As Maintenance in a Community-Based Newly Diagnosed Myeloma Population: Updated Analysis of EMN01 Phase III Study

12. Minimal residual disease (MRD) monitoring by multiparameter flow cytometry (MFC) in newly diagnosed transplant eligible multiple myeloma (MM) patients: Results from the EMN02/HO95 phase 3 trial.

13. Prognostic Implication of Somatic Mutations by Next Generation Sequencing: an Analysis from the MMRF CoMMpass Study in Newly Diagnosed Multiple Myeloma Patients

14. Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis.

15. Prognostic Impact of Minimal Residual Disease By ASO-RQ-PCR in Multiple Myeloma: A Pooled Analysis of 2 Phase III Studies in Patients Treated with Lenalidomide after Front-Line Therapy

16. Prognostic Implication of Somatic Mutations By Next Generation Sequencing: An Analysis from the Mmrf Commpass Study in Newly Diagnosed Multiple Myeloma Patients

17. Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis

18. High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib

19. Minimal Residual Disease Detection By Multiparametric Flow Cytometry in Newly Diagnosed Multiple Myeloma Patients: A Preliminary Analysis of the EMN02/HO95 MM Study

22. Proteomic Characterization of the Multiple Myeloma Bone Marrow Extracellular Matrix

23. In Multiple Myeloma, Minimal Residual Disease (MRD) Is an Early Predictor of Progression and Is Modulated By Maintenance Therapy with Lenalidomide

25. Minimal Residual Disease Monitoring During Maintenance In Multiple Myeloma Patients

26. Improved Igh-Based MRD Detection By Using Droplet Digital PCR: a Comparison With Real Time Quantitative PCR In MCL and MM

27. miRNA in Serum and Bone Marrow Plasma Cells From Multiple Myeloma Patients.

28. High Expression of mRNA and Gene Amplification of Met In Myeloma Plasma Cells Characterize a More Aggressive Disease

29. Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis.

30. High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib.

Catalog

Books, media, physical & digital resources